Optimization research on Perfecting Proprietary Right Protection System of New Test Data in China
Xu Zhihua1,Huang Li'na1,2
1.School of Law, Zhongnan University of Economics and Law, Wuhan 430073,China;2.School of Law, Guangxi University of Finance and Economics, Nanning 530003,China
徐智华,黄丽娜. 我国新药试验数据专有权保护制度优化研究[J]. 科技进步与对策, 2017, 34(10): 139-142.
Xu Zhihua,Huang Li'na. Optimization research on Perfecting Proprietary Right Protection System of New Test Data in China. SCIENCE & TECHNOLOGY PROGRESS AND POLICY, 2017, 34(10): 139-142.
［1］叶云卿.药品试验资料专属权近期国际发展之趋势——我国资料专属权制度及因应国际趋势应有之调整［J］.政大智慧财产评论，2013(11):41.
［2］FORD N.Patents,access to medicines and the role of non-gov-ernmental organizations［J］.J Gene Med，2004,1(2):137.
［3］CHRISTINE D.Gallraith，dying to know:a demand for genuine public access to clinical trial results data［J］.Mis.L.Rev，2009(9):705-710.
［4］全球制药企业研发数据比较［EB/OL］www.askci.com/news/data/2014/10/14/154316tx28.shtm，2014.
［5］AARON X F.Secrecy,monopoly and access to pharmaceuticals in international trade law［R］.Protection of Marketing Approval Data Under the TRIPS Agreement 45 HARV INTLLJ，2004(6):443-465.
［6］梁志文.药品数据保护的比较分析与立法选择［J］.政法论丛，2014（4）: 82.
